MedTrace Logo

Study of AK112 in the Treatment of Advanced Gynecological Tumors

NCT04870177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-02-28

No results posted yet for this study

Summary

A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.

Conditions

  • Gynecologic Cancer
  • Cancer Metastatic
  • Ovarian Neoplasms
  • Cervical Neoplasm
  • Endometrial Neoplasms

Interventions

DRUG

AK112

AK112 infusion biweekly

Sponsors & Collaborators

Principal Investigators

  • Beihua Kong, MD · Qilu Hospital of Shandong University

  • Qi Zhou, MD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2024-05-10
Completion
2024-05-10

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04870177 on ClinicalTrials.gov